1921
Volume 97, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

A tetravalent dengue vaccine (CYD-TDV) has recently been approved in 12 countries in southeast Asia and Latin America for individuals aged 9–45 years or 9–60 years (age indication approvals vary by country) living in endemic areas. Data on utilization of medical and nonmedical resources as well as time lost from school and work were collected during the active phase of two phase III efficacy studies performed in 10 countries in the Asia-Pacific region and Latin America (NCT01373281; NCT01374516). We compared dengue-related resource utilization and costs among vaccinated and nonvaccinated participants. Country-specific unit costs were derived from available literature. There were 901 virologically confirmed dengue episodes among participants aged ≥ 9 years ( = 25,826): corresponding to 373 episodes in the CYD-TDV group ( = 17,230) and 528 episodes in the control group ( = 8,596). Fewer episodes in the CYD-TDV group resulted in hospitalization than in the control group (7.0% versus 13.3%; = 0.002), but both had a similar average length of stay of 4 days. Overall, a two-thirds reduction in resource consumption and missed school/work days was observed in the CYD-TDV group relative to the control group. The estimated direct and indirect cost (2014 I$) associated with dengue episodes per participant in the CYD-TDV group was 73% lower than in the control group (I$6.72 versus I$25.08); representing a saving of I$I8.36 (95% confidence interval [CI]:17.05–19.78) per participant with vaccination. This is the first study providing information on dengue costs among vaccinated individuals and direct confirmation that vaccination has the potential to reduce dengue illness costs.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0952
2017-12-06
2018-11-15
Loading full text...

Full text loading...

/deliver/fulltext/14761645/97/6/tpmd160952.html?itemId=/content/journals/10.4269/ajtmh.16-0952&mimeType=html&fmt=ahah

References

  1. Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, Moyes CL, Farlow AW, Scott TW, Hay SI, , 2012. Refining the global spatial limits of dengue virus transmission by evidence-based consensus. PLoS Negl Trop Dis 6: e1760.
  2. World Health Organization, 2012. Global Strategy for Dengue Prevention and Control. Available at: http://apps.who.int/iris/bitstream/10665/75303/1/9789241504034_eng.pdf. Accessed October 5, 2015.
  3. Murray NE, Quam MB, Wilder-Smith A, , 2013. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol 5: 299309.
  4. Messina JP, 2014. Global spread of dengue virus types: mapping the 70 year history. Trends Microbiol 22: 138146.
  5. Shepard DS, Coudeville L, Halasa YA, Zambrano B, Dayan GH, , 2011. Economic impact of dengue illness in the Americas. Am J Trop Med Hyg 84: 200207.
  6. Shepard DS, Undurraga EA, Halasa YA, , 2013. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis 7: e2055.
  7. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD, , 2016. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis 16: 935941.
  8. Villar L, 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372: 113123.
  9. Capeding MR, 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384: 13581365.
  10. Durham DP, Ndeffo Mbah ML, Medlock J, Luz PM, Meyers LA, Paltiel AD, Galvani AP, , 2013. Dengue dynamics and vaccine cost-effectiveness in Brazil. Vaccine 31: 39573961.
  11. Carrasco LR, 2011. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Negl Trop Dis 5: e1426.
  12. Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DN, Meltzer MI, , 2004. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22: 12751280.
  13. Orellano PW, Salomon OD, , 2016. Will dengue vaccination be cost-effective for Argentina? Reply to letter by Uruena et al. regarding “Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission”. Vaccine 34: 3221.
  14. Flasche S, 2016. The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): a model comparison study. PLoS Med 13: e1002181.
  15. Shim E, , 2016. Dengue dynamics and vaccine cost-effectiveness analysis in the Philippines. Am J Trop Med Hyg 95: 11371147.
  16. Suaya JA, 2009. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am J Trop Med Hyg 80: 846855.
  17. International Monetary Fund, 2014. World Economic Outlook Databases. Available at: http://www.imf.org/external/ns/cs.aspx?id=28. Accessed April 2014.
  18. Shepard DS, Hodgkin D, Anthony YE;, World Health Organization, 2000. Analysis of Hospital Costs: A Manual for Managers. Geneva, Switzerland: World Health Organization. Available at: http://apps.who.int/iris/bitstream/10665/42197/1/9241545283.pdf. Accessed October 6, 2015.
  19. Sanofi Pastuer, 2015. Press Release: New England Journal of Medicine Publishes New Analyses Confirming that Sanofi Pasteur’s Vaccine Candidate Safely Protects Pre-Adolescents to Adults Against Dengue. Available at: http://www.sanofipasteur.com/en/Documents/PDF/PR/SP%20NEJM.PDF. Accessed October 7, 2015.
  20. Hadinegoro SR, 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373: 11951206.
  21. Lee BY, Connor DL, Kitchen SB, Bacon KM, Shah M, Brown ST, Bailey RR, Laosiritaworn Y, Burke DS, Cummings DA, , 2011. Economic value of dengue vaccine in Thailand. Am J Trop Med Hyg 84: 764772.
  22. Kongsin S, Jiamton S, Suaya JA, Vasanwathan S, Sirisuvan P, Shepard DS, , 2010. Cost of dengue in Thailand. Dengue Bull 34: 7788.
  23. Vieira Machado AA, Estevan AO, Sales A, Brabes KC, Croda J, Negrao FJ, , 2014. Direct costs of dengue hospitalization in Brazil: public and private health care systems and use of WHO guidelines. PLoS Negl Trop Dis 8: e3104.
  24. Khan NA, Azhar EI, El-Fiky S, Madani HH, Abuljadial MA, Ashshi AM, Turkistani AM, Hamouh EA, , 2008. Clinical profile and outcome of hospitalized patients during first outbreak of dengue in Makkah, Saudi Arabia. Acta Trop 105: 3944.
  25. Streit JA, Yang M, Cavanaugh JE, Polgreen PM, , 2011. Upward trend in dengue incidence among hospitalized patients, United States. Emerg Infect Dis 17: 914916.
  26. Lye DC, Chan M, Lee VJ, Leo YS, , 2008. Do young adults with uncomplicated dengue fever need hospitalisation? A retrospective analysis of clinical and laboratory features. Singapore Med J 49: 476479.
  27. Khalil MA, Tan J, Awan S, Rangasami M, , 2014. Predictors of hospital stay and mortality in dengue virus infection-experience from Aga Khan University Hospital Pakistan. BMC Res Notes 7: 473.
  28. Halasa YA, Shepard DS, Zeng W, , 2012. Economic cost of dengue in Puerto Rico. Am J Trop Med Hyg 86: 745752.
  29. Undurraga EA, 2015. Economic and disease burden of dengue in Mexico. PLoS Negl Trop Dis 9: e0003547.
  30. Clark DV, Mammen MP, Jr Nisalak A, Puthimethee V, Endy TP, , 2005. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg 72: 786791.
  31. Martelli CM, 2015. Economic impact of dengue: multicenter study across four Brazilian regions. PLoS Negl Trop Dis 9: e0004042.
  32. Armien B, Suaya JA, Quiroz E, Sah BK, Bayard V, Marchena L, Campos C, Shepard DS, , 2008. Clinical characteristics and national economic cost of the 2005 dengue epidemic in Panama. Am J Trop Med Hyg 79: 364371.
  33. Huy R, Wichmann O, Beatty M, Ngan C, Duong S, Margolis HS, Vong S, , 2009. Cost of dengue and other febrile illnesses to households in rural Cambodia: a prospective community-based case-control study. BMC Public Health 9: 155.
  34. Beaute J, Vong S, , 2010. Cost and disease burden of dengue in Cambodia. BMC Public Health 10: 521.
  35. Baly A, Toledo ME, Rodriguez K, Benitez JR, Rodriguez M, Boelaert M, Vanlerberghe V, Van der Stuyft P, , 2012. Costs of dengue prevention and incremental cost of dengue outbreak control in Guantanamo, Cuba. Trop Med Int Health 17: 123132.
  36. Wettstein ZS, Fleming M, Chang AY, Copenhaver DJ, Wateska AR, Bartsch SM, Lee BY, Kulkarni RP, , 2012. Total economic cost and burden of dengue in Nicaragua: 1996–2010. Am J Trop Med Hyg 87: 616622.
  37. Salmon-Mulanovich G, Blazes DL, Lescano AG, Bausch DG, Montgomery JM, Pan WK, , 2015. Economic burden of dengue virus infection at the household level among residents of Puerto Maldonado, Peru. Am J Trop Med Hyg 93: 684690.
  38. Castro Rodriguez R, Galera-Gelvez K, Lopez Yescas JG, Rueda-Gallardo JA, , 2015. Costs of dengue to the health system and individuals in Colombia from 2010 to 2012. Am J Trop Med Hyg 92: 709714.
  39. Lim LH, 2010. Immediate cost of dengue to Malaysia and Thailand: an estimate. Dengue Bull 34: 6576.
  40. Tam PT, Dat NT, , Huu le M, Thi XC, Duc HM, Tu TC, Kutcher S, Ryan PA, Kay BH, 2012. High household economic burden caused by hospitalization of patients with severe dengue fever cases in Can Tho province, Vietnam. Am J Trop Med Hyg 87: 554558.
  41. Shepard DS, Undurraga EA, Lees RS, Halasa Y, Lum LC, Ng CW, , 2012. Use of multiple data sources to estimate the economic cost of dengue illness in Malaysia. Am J Trop Med Hyg 87: 796805.
  42. Edillo FE, Halasa YA, Largo FM, Erasmo JN, Amoin NB, Alera MT, Yoon IK, Alcantara AC, Shepard DS, , 2015. Economic cost and burden of dengue in the Philippines. Am J Trop Med Hyg 92: 360366.
  43. Garg P, Nagpal J, Khairnar P, Seneviratne SL, , 2008. Economic burden of dengue infections in India. Trans R Soc Trop Med Hyg 102: 570577.
  44. Shepard DS, Halasa YA, Tyagi BK, Adhish SV, Nandan D, Karthiga KS, Chellaswamy V, Gaba M, Arora NK, , 2014. Economic and disease burden of dengue illness in India. Am J Trop Med Hyg 91: 12351242.
  45. Rafique I, Nadeem Saqib MA, Munir MA, Qureshi H, Siddiqui S, Habibullah S, Bashir S, Rehman S, Ashraf S, , 2015. Economic burden of dengue in four major cities of Pakistan during 2011. J Pak Med Assoc 65: 256259.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0952
Loading
/content/journals/10.4269/ajtmh.16-0952
Loading

Data & Media loading...

Supplementary Data

Supplemental Appendix

  • Received : 06 Dec 2016
  • Accepted : 10 Jun 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error